ZYME
Zymeworks Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website zymeworks.com
- Employees(FY) 252
- ISIN US98985Y1082
Performance
-1.19%
1W
+2.13%
1M
-24.13%
3M
+17.22%
6M
-12.22%
YTD
-0.76%
1Y
Profile
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Investment Analysis Report: ZYME
Overview
In this investment analysis report, we will delve into a comprehensive analysis of ZYME, a company operating in the Health Technology sector with a focus on Pharmaceuticals. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash flow, ...
Technical Analysis of ZYME 2024-05-10
Overview:
In analyzing the technical indicators for ZYME over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential invest...
Recent News & Updates
- 2024-05-16 04:20
- 2024-05-05 08:06
- 2024-05-02 16:05
- 2024-05-02 04:05
- 2024-04-30 06:00
- 2024-04-29 18:00
- 2024-04-28 10:26
We Think Zymeworks (NASDAQ:ZYME) Can Afford To Drive Business Growth(Simply Wall St.)
- 2024-04-11 06:00
- 2024-04-10 18:00
- 2024-04-09 21:35
- 2024-04-08 06:00
- 2024-04-07 18:00
- 2024-03-28 06:00
- 2024-03-27 18:00
- 2024-03-27 06:00
- 2024-03-26 18:00
- 2024-03-22 00:00
- 2024-03-11 00:44
20 Highest Paying Countries for Biotechnology(Insidermonkey)
- 2024-03-09 00:09
- 2024-03-06 17:39
- 2024-03-06 16:09
- 2024-03-06 09:53
- 2024-03-06 03:09
- 2024-03-05 16:30
- 2024-03-05 03:30
- 2024-02-27 21:00
- 2024-02-27 06:00
- 2024-02-26 17:00
- 2024-02-14 06:00
- 2024-02-13 17:00
Page 1 of 5
previousnext